Table 1.
STING agonists in the development process.
| Drug Name | Category | Therapy Area | Status |
|---|---|---|---|
| ADU-S100 | CDN | Cancer | Phase II (Termination) |
| MK-1454 | CDN | Cancer | Phase II (Termination) |
| GB492 | CDN | Cancer | Phase I/II |
| BMS-986301 | CDN | Cancer | Phase I |
| E7766 | CDN | Cancer | Phase I |
| SB11285 | CDN | Cancer;Infection | Phase I |
| GSK3745417 | Non-CDN | Cancer;Infection | Phase I |
| TAK-676 | Non-CDN | Cancer | Phase I |
| SNX281 | Non-CDN | Cancer | Phase I |
| HG381 | Non-CDN | Cancer | IND |
| CRD-100 | Non-CDN | Cancer | Pre-clinical |
| CRD5500 | Non-CDN | Cancer | Pre-clinical |
| TTI-10001 | Non-CDN | Cancer | Pre-clinical |
| AN3005 | Non-CDN | Cancer | Pre-clinical |
| HH18202 | Non-CDN | Cancer | Pre-clinical |
| XMT-2056 | ADC | Cancer | Phase I |
| TAK-500 | ADC | Cancer | Phase I |
| exoSTING | CDN+exosome | Cancer | Phase I/II |
| SYNB1891 | Engineered Bacteria | Cancer | Phase I |